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Abstract 
Hemorrhagic telangiectasia (HHT) is a disease of initially mild course - manifesting with recurrent nosebleeds and increased fatigue. Ne-
vertheless, its progression can deteriorate patient’s health. Solid organ transplantation becomes the only therapeutic option to save a life. 
The case report describes a 19-year-old female patient who was diagnosed with HHT and qualified for lung transplantation. She 
met the Curacao criteria for HHT (¾).  Her health deteriorated significantly to the point of the referral to Department of Cardiac,
Vascular and Endovascular Surgery and Transplantology in Silesian Center for Heart Diseases. Due to her condition, she was 
qualified for lung transplantation as one diagnosed with pulmonary arteriovenous malformations and then transplanted at the age 
of 17. A direct postoperative period was complicated by HSV2 infection of the wound. 18 months after the procedure, the patient 
underwent acute cholangitis. The presence of portal and systemic fistulas was noted and the final diagnosis of HHT was made. 
Despite the fact that proper diagnosis was made posttransplant, it was a good treatment. The patient is currently 2 years after 
the lung transplantation and feels good.
Lung transplantation is a viable therapeutic option for patients with HHT as there are reports of other patients who have benefited 
from lung transplantation after other therapeutic options were exhausted. 
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Introduction
Osler-Rendu-Weber syndrome also known as 
hereditary hemorrhagic telangiectasia (HHT) is 
an autosomal-dominant disease that affects 1 in 
5,000–8,000 people [1]. Its presentation patterns 
are highly variable. Some of the symptoms such 
as epistaxis could manifest before school age [2]. 
Pulmonary arteriovenous malformations (PAVM) 
are estimated to be present among 30–50% of 
patients with HHT. The prevalence of dyspnea 
among those patients reaches 35% [3]. Abnormal 
vascular structures can be also present in the 
liver [1]. Its symptomatic involvement includes 
high-output heart failure, portal hypertension, 
and biliary disease [4]. Therapeutic options 
for HHT patients include embolization and 
segmental or lobar resections of the lungs [5]. 
Sporadic PAVM can be treated by transcatheter 
embolotherapy with Amplatz vascular plugs or 
coils. This safe method provides great radiolog-
ical and functional improvement of the patient 
[6]. However, subjects with HHT and PAVMs face 
higher risk of embolic complication [7]. Solid 
organ transplantation, especially lung trans-
plantation can be a viable therapeutic option 
for patients with HHT and PAVMs [5, 8, 9]. Not 
only it improves the hypoxemia, but it also has 
a positive effect on the cerebral arteriovenous 
malformations [8]. 
Magdalena Latos et al., 2-year follow-up of Lung transplantation as a treatment of Hereditary hemorrhagic telangiectasia
203www.journals.viamedica.pl
Table 1.  6-minute walk test  and spirometry results of female patient after lung transplantation
Number of 
days after 
transplantation
Distance 
[m]
Borg 
Scale
Saturation 
before test
Saturation after 
test
FEV1 acquired 
[L]
FEV1 % FVC 
acquired 
[L]
FVC %
75 93.6 3 93 92 0.97 30 1.2 32
100 260.5 2 95 96 1.2 41 1.36 39
131 341 1 98 94 1.35 48 1.46 44
163 378 1 97 97 1.38 49 1.73 52
225 396.9 1 97 96 1.25 44 1.85 55
309 401 1 98 96 1.49 53 2.14 64
376 389.2 1 97 97 1.6 50 2.04 56
526 440.9 1 98 95 1.57 47 2.13 57
596 441 0,5 99 98 1.52 47 2.38 64
719 455.3 1 99 97 1.64 50 2.37 64
Case presentation: The case report describes 
a female patient whose first symptoms were ob-
served when she was few years old. Back then, she 
reported increased fatigue, post-workout fainting 
and temporary dry, tiring cough. At the beginning 
she was diagnosed with allergy and asthma. De-
spite the treatment, her condition deteriorated. 
She presented following symptoms: increased 
fatigue and central and peripheral cyanosis. Full 
blood count revealed polycythemia. Arterial blo-
od gas test showed hypoxemia with hypercapnia. 
Fainting after physical exercise persisted. At 
the age of 14, the patient underwent computed 
tomography of the chest, which revealed inflam-
matory changes to be differentiated with chronic 
interstitial lung disease. Additionally, lung scin-
tigraphy was performed when the patient was 
15 years old. Lung perfusion scan of 3mCi with 
99mcTc displayed intrapulmonary fistulas. Brain
-lungs ratio was 11.5% (normal limit is less than 
0.4%). The girl was then diagnosed with pulmo-
nary arteriovenous malformations (PAVMs). Due 
to constant deterioration of her health (saturation 
of 81%, post-workout desaturations of 46–50%, 
persistent central cyanosis and necessary oxygen 
treatment), she was referred to, and subsequently 
qualified for lung transplantation in Department 
of Cardiac, Vascular and Endovascular Surgery 
and Transplantology in Silesian Center for Heart 
Diseases. At qualification, she required 2 l/min 
of supplemental oxygen at rest. Abdominal CT 
angiography did not reveal any abnormalities at 
that time. She underwent double lung transplan-
tation at the age of 17 after 378 days spent on Lung 
Transplantation Waiting List. Post-op course was 
complicated with HSV infection, but the rest of 
the recovery period remained uneventful. She 
was treated with ATG as induction of immu-
nosuppression and tacrolimus, encortolon and 
mycophenolate mofetil as immunosuppressive 
maintenance treatment. Pulmonary function was 
satisfactory and stable for the first 2 years after 
transplantation. Detailed results of 6-minute walk 
test (6MWT) and spirometry were presented in 
Table 1. 18 months after lung transplantation 
the patient was hospitalized due to pain in the 
right hypochondrium with nausea and stool di-
scoloration. Diagnosis of acute cholangitis was 
made. Liver enzymes were also elevated (alanine 
aminotransferase 186 IU/l, aspartate aminotrans-
ferase 310 IU/L). CT scans of the liver, MR of the 
liver and bile ducts and Doppler ultrasound of 
the portal system were performed, after which 
suspicion of secondary changes of sclerosing 
cholangitis in the course of ischemic changes due 
to portal and systemic fistulas causing perfusion 
disorders in the liver parenchyma was aroused. 
The presence of this additional feature made us 
rethink the original diagnosis, which was chan-
ged posttransplant. Entire clinical presentation 
of the disease (history of multiple arteriovenous 
fistulas in the lungs and liver, oral telangiecta-
sias and nosebleeds) as well as a positive family 
history (hemorrhage from first-line relatives) met 
the current Curacao criteria of the Osler-Weber- 
Rendu syndrome (HHT) diagnosis. Nowadays, 
the patient is alive and well. The intensity of 
changes is not an indication for endoscopic re-
trograde cholangiopancreatography (ERCP). After 
the transplantation, recurrent nosebleeds, pallor 
of the skin, numerous telangiectasia on the oral 
mucosa and gums are still reported. 
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Discussion 
Even though the proper diagnosis of HHT 
was made after the transplantation carried out 
in the female patient, decision to proceed with 
this therapeutic option was a good choice. It has 
been 2 years since the lung transplantation was 
performed. The 19-year-old patient is alive and 
well. Fukushima et al. [8] presented the case of a 
female patient with HHT who was qualified for 
bilateral lung transplantation and successfully 
transplanted at the age of 18 after waiting 4 years 
for a graft. 38 months after the transplantation, 
the Japanese patient was able to achieve the result 
of 575m during 6MWT. The subject described 
in this case report walked the distance of 455m 
during the same examination 24 months after 
lung transplantation. Another case of pediatric 
lung transplantation in a 4-year-old patient was 
presented by Misra et al. [5]. For 2.5 years after 
the transplantation the patient did well, but due 
to severe deterioration of her pulmonary con-
dition, she was retransplanted the following year. 
After developing Epstein-Barr-virus-associated 
lymphocytic bronchiolitis that evolved into a 
polyclonal post-transplant lymphoproliferative 
disease and proper treatment, the rest of the post-
transplant time was uneventful. At last check-up, 
which was 10 years after first lung transplanta-
tion, she reported increased exercise tolerance, 
with only occasional shortness of breath . The 
girl described in this case report also presented 
similar state of pulmonary function as the Borg 
scale score at her last check-up was 1. It is worth 
mentioning that both patients (the described in 
this case and the presented by Misra et al. [5]) 
were treated with tacrolimus and glucocortocoste-
roids. Both of them reported occasional epistaxis 
after transplantation. Older patients with HHT 
can also benefit from lung transplantation, as it 
has been proved by case report presented by Sve-
tliza et al. [9]. A 39-year-old female patient with 
multiple bilateral atrioventricular fistulas (AVF) 
secondary to hereditary hemorrhagic telangiecta-
sia (HHT) underwent single right lung transplan-
tation after previous left upper lobectomy. After 
2 years and 10 months she is alive and performs 
normal activities. Her 6-minute walk distance at 
this time was 500m, similar to the result obtained 
by the patient described in this case report. The 
39-year-old patient described by Svetliza et al. [9] 
obtained 80% of predicted FEV1 while the female 
patient described in this case presented with 50% 
of predicted FEV1 within similar follow-up time.
To summarize, lung transplantation is a via-
ble treatment among HHT patients with PAVMs. 
Increased lung function is not the only benefit of 
such treatment. What it more, the proper diagnosis 
of HHT is an important element on the way to suc-
cessful transplantation and patient’s well-being. 
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